Phase II study of teniposide in advanced breast cancer
In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therape...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1990-01, Vol.25 (6), p.463-464 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 464 |
|---|---|
| container_issue | 6 |
| container_start_page | 463 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 25 |
| creator | BOAS, J RASMUSSEN, D HANSEN, O. P ENGELHOLM, S. A DOMBERNOWSKY, P |
| description | In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer. |
| doi_str_mv | 10.1007/BF00686061 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00686061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2311176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-6c5b7732c1596cd118f8ddfeb3d33334c6ced0ced32395060e7ed419e2e1e6f73</originalsourceid><addsrcrecordid>eNpFj01LAzEQhoMotVYv3oUcPAmrMzvZZHvUYrVQ0IOel2wywZV-kWyF_nsjLXVgGIb3YYZHiGuEewQwD09TAF1r0HgihqioLKBWdCqGQEoVlQF1Li5S-gYAhUQDMSgJEY0eCv3-ZRPL2Uymfut3ch1kz6tus06dZ9mtpPU_duXYyzayTb10f1u8FGfBLhJfHeZIfE6fPyavxfztZTZ5nBcuP-gL7arWGCodVmPtPGIdau8Dt-Qpl3I6X4bcVNK4Ag1s2Cscc8nIOhgaibv9XRfXKUUOzSZ2Sxt3DULz5978u2f4Zg9vtu2S_RE9yOb89pDb5OwixKzSpSOma1WVWtEvmNNe7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II study of teniposide in advanced breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>BOAS, J ; RASMUSSEN, D ; HANSEN, O. P ; ENGELHOLM, S. A ; DOMBERNOWSKY, P</creator><creatorcontrib>BOAS, J ; RASMUSSEN, D ; HANSEN, O. P ; ENGELHOLM, S. A ; DOMBERNOWSKY, P</creatorcontrib><description>In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00686061</identifier><identifier>PMID: 2311176</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Chemotherapy ; Drug Administration Schedule ; Drug Evaluation ; Female ; Humans ; Infusions, Intravenous ; Leukopenia - chemically induced ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Podophyllotoxin - analogs & derivatives ; Teniposide - administration & dosage ; Teniposide - adverse effects ; Teniposide - therapeutic use ; Thrombocytopenia - chemically induced</subject><ispartof>Cancer chemotherapy and pharmacology, 1990-01, Vol.25 (6), p.463-464</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-6c5b7732c1596cd118f8ddfeb3d33334c6ced0ced32395060e7ed419e2e1e6f73</citedby><cites>FETCH-LOGICAL-c311t-6c5b7732c1596cd118f8ddfeb3d33334c6ced0ced32395060e7ed419e2e1e6f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6845264$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2311176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BOAS, J</creatorcontrib><creatorcontrib>RASMUSSEN, D</creatorcontrib><creatorcontrib>HANSEN, O. P</creatorcontrib><creatorcontrib>ENGELHOLM, S. A</creatorcontrib><creatorcontrib>DOMBERNOWSKY, P</creatorcontrib><title>Phase II study of teniposide in advanced breast cancer</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy</subject><subject>Drug Administration Schedule</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Leukopenia - chemically induced</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Podophyllotoxin - analogs & derivatives</subject><subject>Teniposide - administration & dosage</subject><subject>Teniposide - adverse effects</subject><subject>Teniposide - therapeutic use</subject><subject>Thrombocytopenia - chemically induced</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFj01LAzEQhoMotVYv3oUcPAmrMzvZZHvUYrVQ0IOel2wywZV-kWyF_nsjLXVgGIb3YYZHiGuEewQwD09TAF1r0HgihqioLKBWdCqGQEoVlQF1Li5S-gYAhUQDMSgJEY0eCv3-ZRPL2Uymfut3ch1kz6tus06dZ9mtpPU_duXYyzayTb10f1u8FGfBLhJfHeZIfE6fPyavxfztZTZ5nBcuP-gL7arWGCodVmPtPGIdau8Dt-Qpl3I6X4bcVNK4Ag1s2Cscc8nIOhgaibv9XRfXKUUOzSZ2Sxt3DULz5978u2f4Zg9vtu2S_RE9yOb89pDb5OwixKzSpSOma1WVWtEvmNNe7w</recordid><startdate>19900101</startdate><enddate>19900101</enddate><creator>BOAS, J</creator><creator>RASMUSSEN, D</creator><creator>HANSEN, O. P</creator><creator>ENGELHOLM, S. A</creator><creator>DOMBERNOWSKY, P</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19900101</creationdate><title>Phase II study of teniposide in advanced breast cancer</title><author>BOAS, J ; RASMUSSEN, D ; HANSEN, O. P ; ENGELHOLM, S. A ; DOMBERNOWSKY, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-6c5b7732c1596cd118f8ddfeb3d33334c6ced0ced32395060e7ed419e2e1e6f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy</topic><topic>Drug Administration Schedule</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Leukopenia - chemically induced</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Podophyllotoxin - analogs & derivatives</topic><topic>Teniposide - administration & dosage</topic><topic>Teniposide - adverse effects</topic><topic>Teniposide - therapeutic use</topic><topic>Thrombocytopenia - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BOAS, J</creatorcontrib><creatorcontrib>RASMUSSEN, D</creatorcontrib><creatorcontrib>HANSEN, O. P</creatorcontrib><creatorcontrib>ENGELHOLM, S. A</creatorcontrib><creatorcontrib>DOMBERNOWSKY, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BOAS, J</au><au>RASMUSSEN, D</au><au>HANSEN, O. P</au><au>ENGELHOLM, S. A</au><au>DOMBERNOWSKY, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of teniposide in advanced breast cancer</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1990-01-01</date><risdate>1990</risdate><volume>25</volume><issue>6</issue><spage>463</spage><epage>464</epage><pages>463-464</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>2311176</pmid><doi>10.1007/BF00686061</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1990-01, Vol.25 (6), p.463-464 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00686061 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy Drug Administration Schedule Drug Evaluation Female Humans Infusions, Intravenous Leukopenia - chemically induced Medical sciences Middle Aged Pharmacology. Drug treatments Podophyllotoxin - analogs & derivatives Teniposide - administration & dosage Teniposide - adverse effects Teniposide - therapeutic use Thrombocytopenia - chemically induced |
| title | Phase II study of teniposide in advanced breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A00%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%20teniposide%20in%20advanced%20breast%20cancer&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=BOAS,%20J&rft.date=1990-01-01&rft.volume=25&rft.issue=6&rft.spage=463&rft.epage=464&rft.pages=463-464&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00686061&rft_dat=%3Cpubmed_cross%3E2311176%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2311176&rfr_iscdi=true |